Proton pump inhibitors reduce the incidence of dysplasia in Barrett's esophagus

Aguirre, Thomas; El-Serag, Hashem; Davis, Stephanie; Bhattacharyya, Achyut; Sampliner, Richard
September 2003
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS23
Academic Journal
An abstract of the article "Proton Pump Inhibitors Reduce the Incidence of Dysplasia in Barrett's Esophagus," by Thomas Aguirre, Hashem El-Serag, Stephanie Davis, Achyut Bhattacharyya and Richard Sampliner is presented.


Related Articles

  • Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's Esophagus. Wang, Judy S; Varro, Andrea; Lightdale, Charles J; Lertkowit, Nantaporn; Slack, Kristen N; Fingerhood, Michael L; Tsai, Wei Yann; Wang, Timothy C; Abrams, Julian A // American Journal of Gastroenterology;May2010, Vol. 105 Issue 5, p1039 

    OBJECTIVES:Proton pump inhibitors (PPIs) are frequently prescribed to patients with Barrett's esophagus (BE), but in a subset, they can induce significant hypergastrinemia. Elevated levels of gastrin have been associated with tumorigenic effects in a number of gastrointestinal cancers. We...

  • CLINICAL OUTCOME OF PATIENTS WITH LOW GRADE DYSPLASIA IN BARRETT'S OESOPHAGUS. Gupta, S.; Amaout, A.; Theodossi, A.; Mendall, M. A. // Gut;Apr2004 Supplement 3, Vol. 53, pA59 

    Barrett's esophagus (BO) is a premalignant condition with histopathological evidence of dysplasia being the best marker of increased cancer risk. Of the 273 patients with histology confirmed BO, there were 45 patients with low grade dysplasia (LGD) and 2 patients with high grade dysplasia...

  • Omeprazole was effective in the short term for uninvestigated dyspepsia. Rabeneck, L.; Souchek, J.; Wristers, k.; Talley, Nicholas J. // ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p70 

    Summarizes a study that determined whether a proton-pump inhibitor is effective in the treatment of patients with uninvestigated dyspepsia. Characterization of the patients; Main outcome measures; Results of the study.

  • Subacute Cutaneous Lupus Erythematosus Induced or Exacerbated by Proton Pump Inhibitors. Dam, Claus; Bygum, Anette // Acta Dermato-Venereologica;2008, Vol. 88 Issue 1, p87 

    A letter to the editor is presented concerning the treatment of subacute cutaneous lupus erythematosus using proton pump inhibitors.

  • PPIs and clopidogrel.  // Critical Care Alert;May2009 Pharmacology Watch, p2 

    The article focuses on the efficiency of proton pump inhibitors (PPIs) in reducing the effect of clopidogrel on platelet aggregate.

  • Pantoprazole intravenous. My-Trang Le; Cano, Steven // Drug Utilization Review;Nov2001, Vol. 17 Issue 11, p1 

    Presents information on pantoprazole, an intravenous form of the benzimidazole proton pump inhibitor class drug. Pharmacokinetics; Pharmacodynamics; Dosage and administration.

  • Biological Plausibility Between Proton Pump Inhibitory Therapy and Hip Fracture: Hypermocysteinemia Can Be the Link. Roblin, Xavier; Phelip, Jean Marc // American Journal of Gastroenterology;Apr2009, Vol. 104 Issue 4, p1052 

    A letter to the editor is presented in response to the article regarding the biological validity of proton pump inhibitory therapy (PPI) and hip fracture in the previous issue.

  • It Is Difficult to Discontinue PPI Treatment in Patients With GERD. Bjornsson, Einar // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p367 

    A letter to the editor is presented in response to an article regarding the development of dyspepsia in healthy volunteers after stopping proton-pump inhibitors (PPI) therapy.

  • Omeprazole.  // Reactions Weekly;8/21/2010, Issue 1315, p37 

    The article describes the case of a 52-year-old woman who took omeprazile for acid reflux and developed burning mouth syndrome-like symptoms.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics